Shilpa Medicare Limited (SHILPAMED.BO)
INR 643.55
(5.66%)
INR 643.55
(5.66%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 318.74 Million INR | 198.15% |
| 2022 | -324.76 Million INR | -153.54% |
| 2021 | 606.62 Million INR | -58.95% |
| 2020 | 1.47 Billion INR | -5.36% |
| 2019 | 1.56 Billion INR | 39.1% |
| 2018 | 1.12 Billion INR | 6.67% |
| 2017 | 1.05 Billion INR | -2.17% |
| 2016 | 1.07 Billion INR | -0.71% |
| 2015 | 1.08 Billion INR | 47.02% |
| 2014 | 736.91 Million INR | -2.61% |
| 2013 | 756.69 Million INR | 59.84% |
| 2012 | 473.42 Million INR | 14.8% |
| 2011 | 412.38 Million INR | -16.43% |
| 2010 | 493.48 Million INR | 15.86% |
| 2009 | 425.95 Million INR | 4186.54% |
| 2008 | -10.42 Million INR | -109.21% |
| 2007 | 113.19 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 140.62 Million INR | -42.61% |
| 2023 Q1 | 11.79 Million INR | 114.66% |
| 2023 Q3 | 45.8 Million INR | 184.21% |
| 2023 FY | 318.74 Million INR | 198.15% |
| 2023 Q4 | 245.02 Million INR | 434.93% |
| 2023 Q2 | 16.11 Million INR | 36.69% |
| 2022 Q2 | -186.63 Million INR | -2299.53% |
| 2022 Q4 | -80.42 Million INR | -21.49% |
| 2022 FY | -324.76 Million INR | -153.54% |
| 2022 Q1 | 8.48 Million INR | -97.13% |
| 2022 Q3 | -66.19 Million INR | 64.53% |
| 2021 FY | 606.62 Million INR | -58.95% |
| 2021 Q2 | 199.6 Million INR | 1156.87% |
| 2021 Q1 | 15.88 Million INR | -81.14% |
| 2021 Q3 | 95.65 Million INR | -52.08% |
| 2021 Q4 | 295.49 Million INR | 208.93% |
| 2020 Q3 | 76.68 Million INR | -83.1% |
| 2020 FY | 1.47 Billion INR | -5.36% |
| 2020 Q1 | 863.11 Million INR | 149.64% |
| 2020 Q2 | 453.79 Million INR | -47.42% |
| 2020 Q4 | 84.22 Million INR | 9.84% |
| 2019 Q4 | 345.74 Million INR | -37.21% |
| 2019 Q2 | 507.75 Million INR | 222.52% |
| 2019 FY | 1.56 Billion INR | 39.1% |
| 2019 Q1 | 157.43 Million INR | -34.08% |
| 2019 Q3 | 550.61 Million INR | 8.44% |
| 2018 Q2 | 422.67 Million INR | 25.64% |
| 2018 FY | 1.12 Billion INR | 6.67% |
| 2018 Q3 | 124.72 Million INR | -70.49% |
| 2018 Q1 | 336.4 Million INR | 10.77% |
| 2018 Q4 | 238.81 Million INR | 91.48% |
| 2017 FY | 1.05 Billion INR | -2.17% |
| 2017 Q3 | 173.02 Million INR | -49.33% |
| 2017 Q2 | 341.48 Million INR | 54.05% |
| 2017 Q1 | 221.67 Million INR | -38.58% |
| 2017 Q4 | 303.68 Million INR | 75.51% |
| 2016 Q1 | 147.16 Million INR | -59.99% |
| 2016 FY | 1.07 Billion INR | -0.71% |
| 2016 Q4 | 360.94 Million INR | 116.82% |
| 2016 Q3 | 166.47 Million INR | -55.02% |
| 2016 Q2 | 370.08 Million INR | 151.49% |
| 2015 Q4 | 367.81 Million INR | 32.7% |
| 2015 FY | 1.08 Billion INR | 47.02% |
| 2015 Q1 | 160.59 Million INR | -28.28% |
| 2015 Q2 | 233.27 Million INR | 45.26% |
| 2015 Q3 | 277.17 Million INR | 18.82% |
| 2014 Q2 | 172.95 Million INR | 1.3% |
| 2014 FY | 736.91 Million INR | -2.61% |
| 2014 Q4 | 223.92 Million INR | 32.26% |
| 2014 Q3 | 169.3 Million INR | -2.11% |
| 2014 Q1 | 170.72 Million INR | -30.89% |
| 2013 Q2 | 135.96 Million INR | -19.72% |
| 2013 FY | 756.69 Million INR | 59.84% |
| 2013 Q4 | 247.03 Million INR | 19.57% |
| 2013 Q3 | 206.59 Million INR | 51.95% |
| 2013 Q1 | 169.36 Million INR | 35.4% |
| 2012 FY | 473.42 Million INR | 14.8% |
| 2012 Q2 | 113.91 Million INR | 6.46% |
| 2012 Q3 | 127.42 Million INR | 11.86% |
| 2012 Q1 | 106.99 Million INR | -36.05% |
| 2012 Q4 | 125.08 Million INR | -1.83% |
| 2011 FY | 412.38 Million INR | -16.43% |
| 2011 Q1 | 107.67 Million INR | 0.0% |
| 2011 Q4 | 167.3 Million INR | 160.86% |
| 2011 Q3 | 64.13 Million INR | -16.14% |
| 2011 Q2 | 76.47 Million INR | -28.97% |
| 2010 FY | 493.48 Million INR | 15.86% |
| 2009 FY | 425.95 Million INR | 4186.54% |
| 2008 FY | -10.42 Million INR | -109.21% |
| 2007 FY | 113.19 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 94.824% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 98.995% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 93.231% |
| Granules India Limited | 4.05 Billion INR | 92.136% |
| Indoco Remedies Limited | 984.6 Million INR | 67.627% |
| Achyut Healthcare Limited | 5.73 Million INR | -5460.747% |
| Ajanta Pharma Limited | 8.16 Billion INR | 96.095% |
| Alkem Laboratories Limited | 17.95 Billion INR | 98.225% |
| Alpa Laboratories Limited | 167.76 Million INR | -89.993% |
| Brooks Laboratories Limited | -195.91 Million INR | 262.691% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 80.265% |
| Bajaj HealthCare Limited | -837.93 Million INR | 138.039% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 57.757% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.428% |
| Eris Lifesciences Limited | 3.91 Billion INR | 91.868% |
| FDC Limited | 3.05 Billion INR | 89.557% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 102.123% |
| Gufic Biosciences Limited | 861.35 Million INR | 62.995% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 92.428% |
| Ipca Laboratories Limited | 5.47 Billion INR | 94.177% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -41.896% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 261.565% |
| Lasa Supergenerics Limited | -217.3 Million INR | 246.679% |
| Laurus Labs Limited | 1.6 Billion INR | 80.147% |
| Lupin Limited | 19.14 Billion INR | 98.335% |
| Mankind Pharma Limited | 19.12 Billion INR | 98.334% |
| Medicamen Biotech Limited | 109.31 Million INR | -191.595% |
| Medico Remedies Limited | 82.9 Million INR | -284.448% |
| Megasoft Limited | -127.46 Million INR | 350.06% |
| NATCO Pharma Limited | 13.88 Billion INR | 97.704% |
| Piramal Pharma Limited | 178.2 Million INR | -78.868% |
| RPG Life Sciences Limited | 876.6 Million INR | 63.639% |
| Sigachi Industries Limited | 571.8 Million INR | 44.257% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.667% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 89.385% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -25.914% |
| Unichem Laboratories Limited | -704.74 Million INR | 145.228% |
| Wanbury Limited | 559.56 Million INR | 43.037% |
| Windlas Biotech Limited | 581.87 Million INR | 45.221% |
| ZIM Laboratories Limited | 172.46 Million INR | -84.817% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.174% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 108.232% |
| Divi's Laboratories Limited | 16 Billion INR | 98.008% |
| Hester Biosciences Limited | 188.89 Million INR | -68.745% |
| Procter & Gamble Health Limited | 2 Billion INR | 84.141% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 29.125% |
| Bal Pharma Limited | 73.92 Million INR | -331.187% |
| Strides Pharma Science Limited | -706.14 Million INR | 145.139% |
| Venus Remedies Limited | 284.9 Million INR | -11.875% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 85.305% |
| Nectar Lifesciences Limited | 49.95 Million INR | -538.122% |
| Aarti Drugs Limited | 1.71 Billion INR | 81.406% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 76.289% |
| Suven Life Sciences Limited | -1.05 Billion INR | 130.334% |
| Ind-Swift Limited | 142.31 Million INR | -123.973% |
| Valiant Laboratories Limited | 3.19 Million INR | -9873.154% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 94.232% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 105.618% |
| Themis Medicare Limited | 435.23 Million INR | 26.766% |
| Hikal Limited | 696.02 Million INR | 54.205% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 98.076% |
| Sequent Scientific Limited | -358.69 Million INR | 188.863% |
| Novartis India Limited | 851.9 Million INR | 62.585% |
| Wockhardt Limited | -4.63 Billion INR | 106.884% |
| Jubilant Pharmova Limited | 771 Million INR | 58.659% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -4394.388% |
| Neuland Laboratories Limited | 3 Billion INR | 89.378% |
| Morepen Laboratories Limited | 961.59 Million INR | 66.853% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -118.296% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 451.359% |